Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David N Church

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
The Journal of Pathology|April 1, 2018
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune responseDaniel Temko, Inge C Van Gool, Emily Rayner, et al.
Journal of the National Cancer Institute|January 17, 2019
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal CancerVictoria Gray, Sarah Briggs, Claire Palles, et al.
Cancer Immunology Research|March 16, 2019
A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human CancerHagma H Workel, Joyce M Lubbers, Roland Arnold, et al.
Cancer Immunology Research|October 1, 2020
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial CancerNanda Horeweg, Marco de Bruyn, Remi A Nout, et al.
Nature Communications|March 17, 2022
Tertiary lymphoid structures critical for prognosis in endometrial cancer patientsNanda Horeweg, Hagma H Workel, Dominik Loiero, et al.
The Lancet. Oncology|February 1, 2024
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysisAnja L Frei, Anthony McGuigan, Ritik R A K Sinha, et al.
The Journal of Pathology. Clinical Research|September 12, 2023
Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasetsAnja L Frei, Anthony McGuigan, Ritik Rak Sinha, et al.
The Lancet. Gastroenterology & Hepatology|July 26, 2018
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based seriesEnric Domingo, Carme Camps, Pamela J Kaisaki, et al.
Nature Medicine|December 16, 2022
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanomaChelsea A Taylor, Robert A Watson, Orion Tong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trialFélix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
The Journal of Pathology|April 1, 2018
Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune responseDaniel Temko, Inge C Van Gool, Emily Rayner, et al.
Journal of the National Cancer Institute|January 17, 2019
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal CancerVictoria Gray, Sarah Briggs, Claire Palles, et al.
Cancer Immunology Research|March 16, 2019
A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human CancerHagma H Workel, Joyce M Lubbers, Roland Arnold, et al.
Cancer Immunology Research|October 1, 2020
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial CancerNanda Horeweg, Marco de Bruyn, Remi A Nout, et al.
Nature Communications|March 17, 2022
Tertiary lymphoid structures critical for prognosis in endometrial cancer patientsNanda Horeweg, Hagma H Workel, Dominik Loiero, et al.
The Lancet. Oncology|February 1, 2024
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysisAnja L Frei, Anthony McGuigan, Ritik R A K Sinha, et al.
The Journal of Pathology. Clinical Research|September 12, 2023
Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasetsAnja L Frei, Anthony McGuigan, Ritik Rak Sinha, et al.
The Lancet. Gastroenterology & Hepatology|July 26, 2018
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based seriesEnric Domingo, Carme Camps, Pamela J Kaisaki, et al.
Nature Medicine|December 16, 2022
IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanomaChelsea A Taylor, Robert A Watson, Orion Tong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2026
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trialFélix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, et al.
Pageof 7